The PSMA-PET scan: a study on tracer properties and test repeatability
- Conditions
- (metastasized) prostate cancer(gemetastaseerde) prostaatkanker
- Registration Number
- NL-OMON24408
- Lead Sponsor
- VU University Medical Center, Amsterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Part A
•Histologically proven prostate cancer, with lymphatic and/or haematogeneous metastases
Exclusion Criteria
•Claustrophobia (part A and B)
•Multiple malignancies (part A and B)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Part A: A pharmacokinetic model for [18F]PSMA ([18F]DCFPyl) and a validated simplified quantitative method for [18F]PSMA PET-CT. <br><br /><br /><br>Part B: Test-retest variability of the derived simplified method (Part A).
- Secondary Outcome Measures
Name Time Method